Vor Biopharma (VOR) Gains from Investment Securities (2025 - 2026)
Vor Biopharma (VOR) posted quarterly Gains from Investment Securities of $188.4 million for Q1 2026, up 110.73% quarter-over-quarter from -$1.8 billion in Q4 2025.
Powered by 
Analysis
Vor Biopharma (VOR) Gains from Investment Securities (2025 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Gains from Investment Securities for 2 consecutive years, with $188.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities changed N/A year-over-year to $188.4 million; the TTM figure through Mar 2026 stood at $522.7 million (changed N/A YoY), while the FY2025 annual figure was $334.4 million, changed N/A from the prior year.
- Gains from Investment Securities climbed to $188.4 million in Q1 2026 per VOR's latest filing, from -$1.8 billion in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.3 billion in Q2 2025 and bottomed at -$1.8 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.30 Mn |
| Mar 31, 2026 | 188.36 Mn |
| Dec 31, 2025 | -1.76 Bn |
| Sep 30, 2025 | 790.46 Mn |
| Jun 30, 2025 | 1.30 Bn |